Opioid Class-Wide REMS May Launch Without Element To Monitor Prescribing
Executive Summary
All metrics for assessing the effectiveness of the Risk Evaluation and Mitigation Strategy for long-acting/extended release opioids may not be in place when FDA approves REMS for individual products.
You may also be interested in...
Hydrocodone Gets Advisory Committee Review, Offering Congress A Scheduling Out
FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.
REMS Need Metrics For Assessing Success, Burden On Health Care System
“We don’t really have clear methods for assessing burden and access,” CDER’s Mary Willy acknowledges. A lack of baseline information hinders the measurement of whether REMS and their components are working.
Pain Prescriber Education Programs Need Better Coordination, GAO Says
FDA and other federal agencies could better coordinate their efforts to educate prescribers about prescription pain reliever abuse, the Government Accountability Office said.